Press release
August 14, 2026
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics, Inc. (NMRA)
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second